Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family

被引:236
作者
Lambeir, AM
Proost, P
Durinx, C
Bal, G
Senten, K
Augustyns, K
Scharpé, S
Van Damme, J
De Meester, I
机构
[1] Univ Antwerp, Med Biochem Lab, Dept Pharmaceut Sci, B-2610 Antwerp, Belgium
[2] Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, B-3000 Louvain, Belgium
[3] Univ Antwerp, Dept Pharmaceut Sci, Med Chem Lab, B-2610 Antwerp, Belgium
关键词
D O I
10.1074/jbc.M103106200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chemokines coordinate many aspects of leukocyte migration. As chemoattractants they play an important role in the innate and acquired immune response. There is good experimental evidence that N-terminal truncation by secreted or cell surface proteases is a way of modulating chemokine action. The localization of CD26/dipeptidyl peptidase IV on cell surfaces and in biological fluids, its primary specificity, and the type of naturally occurring truncated chemokines are consistent with such a function. We determined the steady-state catalytic parameters for a relevant selection of chemokines (CCL3b, CCL5, CCL11, CCL22, CXCL9, CXCL10, CXCL11, and CXCL12) previously reported to alter their chemotactic behavior due to CD26/dipeptidyl peptidase IV-catalyzed truncation. The results reveal a striking selectivity for stromal cell-derived factor-la (CXCL12) and macrophage-derived chemokine (CCL22). The kinetic parameters support the hypothesis that CD26/dipeptidyl peptidase IV contributes to the degradation of certain chemokines in vivo. The data not only provide insight into the selectivity of the enzyme for specific chemokines, but they also contribute to the general understanding of CD26/dipeptidyl peptidase IV secondary substrate specificity.
引用
收藏
页码:29839 / 29845
页数:7
相关论文
共 62 条
[1]   Chemokines and leukocyte traffic [J].
Baggiolini, M .
NATURE, 1998, 392 (6676) :565-568
[2]   Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors [J].
Belyaev, A ;
Zhang, XM ;
Augustyns, K ;
Lambeir, AM ;
De Meester, I ;
Vedernikova, I ;
Scharpé, S ;
Haemers, A .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (06) :1041-1052
[3]   Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease [J].
Berger, EA ;
Murphy, PM ;
Farber, JM .
ANNUAL REVIEW OF IMMUNOLOGY, 1999, 17 :657-700
[4]   KINETICS OF DIPEPTIDYL PEPTIDASE-IV PROTEOLYSIS OF GROWTH HORMONE-RELEASING FACTOR AND ANALOGS [J].
BONGERS, J ;
LAMBROS, T ;
AHMAD, M ;
HEIMER, EP .
BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1122 (02) :147-153
[5]  
BREZINSCHEK RI, 1995, J IMMUNOL, V154, P3062
[6]   Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1 [J].
Crump, MP ;
Gong, JH ;
Loetscher, P ;
Rajarathnam, K ;
Amara, A ;
Arenzana-Seisdedos, F ;
Virelizier, JL ;
Baggiolini, M ;
Sykes, BD ;
Clark-Lewis, I .
EMBO JOURNAL, 1997, 16 (23) :6996-7007
[7]   Solution structure of eotaxin, a chemokine that selectively recruits eosinophils in allergic inflammation [J].
Crump, MP ;
Rajarathnam, K ;
Kim, KS ;
Clark-Lewis, I ;
Sykes, BD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (35) :22471-22479
[8]   Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1α, MIP-1β, and RANTES -: Characterization of active disaggregated chemokine variants [J].
Czaplewski, LG ;
McKeating, J ;
Craven, CJ ;
Higgins, LD ;
Appay, V ;
Brown, A ;
Dudgeon, T ;
Howard, LA ;
Meyers, T ;
Owen, J ;
Palan, SR ;
Tan, P ;
Wilson, G ;
Woods, NR ;
Heyworth, CM ;
Lord, BI ;
Brotherton, D ;
Christison, R ;
Craig, S ;
Cribbes, S ;
Edwards, RM ;
Evans, SJ ;
Gilbert, R ;
Morgan, P ;
Randle, E ;
Schofield, N ;
Varley, PG ;
Fisher, J ;
Waltho, JP ;
Hunter, MG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (23) :16077-16084
[9]   CD26, let it cut or cut it down [J].
De Meester, I ;
Korom, S ;
Van Damme, J ;
Scharpé, S .
IMMUNOLOGY TODAY, 1999, 20 (08) :367-375
[10]  
Delgado MB, 2001, EUR J IMMUNOL, V31, P699, DOI 10.1002/1521-4141(200103)31:3<699::AID-IMMU699>3.0.CO